BR112015001502A2 - derivados de tipo azaindazol ou diazaindazol para tratamento de dor - Google Patents

derivados de tipo azaindazol ou diazaindazol para tratamento de dor

Info

Publication number
BR112015001502A2
BR112015001502A2 BR112015001502A BR112015001502A BR112015001502A2 BR 112015001502 A2 BR112015001502 A2 BR 112015001502A2 BR 112015001502 A BR112015001502 A BR 112015001502A BR 112015001502 A BR112015001502 A BR 112015001502A BR 112015001502 A2 BR112015001502 A2 BR 112015001502A2
Authority
BR
Brazil
Prior art keywords
mixture
diazaindazole
azaindazole
derivatives
pain management
Prior art date
Application number
BR112015001502A
Other languages
English (en)
Other versions
BR112015001502B1 (pt
Inventor
Cachoux Frédéric
Sokoloff Pierre
Original Assignee
Pf Medicament
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pf Medicament filed Critical Pf Medicament
Publication of BR112015001502A2 publication Critical patent/BR112015001502A2/pt
Publication of BR112015001502B1 publication Critical patent/BR112015001502B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

abstract the present invention relates to a compound of following formula (i): (i) or a pharmaceutically acceptable salt or solvate of same, a tautomer of same, or a stereoisomer or mixture of stereoisomers of same in any proportions, such as a mixture of enantiomers, notably a racemic mixture; for use in the treatment of pain. tradução do resumo resumo patente de invenção: "derivados de tipo azaindazol ou diazaindazol para tratamento de dor". a presente invenção refere-se a um composto da fórmula (i) que segue: ou um sal farmaceuticamente aceitável ou solvato do mesmo, um tautômero do mesmo, um estereoisômero ou mistura de estereoisômeros do mesmo em quaisquer proporções, tal como uma mistura de enantiômeros, notadamente uma mistura racêmica; para uso no tratamento de dor. 23654790v1 23654790v1
BR112015001502-6A 2012-07-27 2013-07-29 Uso de derivados de tipo azaindazol ou diazaindazol no tratamento ou prevenção de dor BR112015001502B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12305922.2A EP2689778A1 (en) 2012-07-27 2012-07-27 Derivatives of azaindoles or diazaindoles for treating pain
EP12305922.2 2012-07-27
PCT/EP2013/065907 WO2014016433A1 (en) 2012-07-27 2013-07-29 Derivatives of azaindazole or diazaindazole type for treating pain

Publications (2)

Publication Number Publication Date
BR112015001502A2 true BR112015001502A2 (pt) 2017-07-04
BR112015001502B1 BR112015001502B1 (pt) 2023-03-07

Family

ID=48948392

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015001502-6A BR112015001502B1 (pt) 2012-07-27 2013-07-29 Uso de derivados de tipo azaindazol ou diazaindazol no tratamento ou prevenção de dor

Country Status (29)

Country Link
US (1) US9381195B2 (pt)
EP (2) EP2689778A1 (pt)
JP (2) JP6456823B2 (pt)
KR (1) KR102120505B1 (pt)
CN (1) CN104684554B (pt)
AU (1) AU2013294920B2 (pt)
BR (1) BR112015001502B1 (pt)
CA (1) CA2879595C (pt)
CY (1) CY1118478T1 (pt)
DK (1) DK2877177T3 (pt)
ES (1) ES2612349T3 (pt)
HK (1) HK1207302A1 (pt)
HR (1) HRP20170104T1 (pt)
HU (1) HUE032919T2 (pt)
IL (1) IL236917A (pt)
LT (1) LT2877177T (pt)
MA (1) MA37866B1 (pt)
MX (1) MX363605B (pt)
MY (1) MY183398A (pt)
NZ (1) NZ705253A (pt)
PL (1) PL2877177T3 (pt)
PT (1) PT2877177T (pt)
RS (1) RS55646B1 (pt)
RU (1) RU2640046C2 (pt)
SI (1) SI2877177T1 (pt)
TN (1) TN2015000034A1 (pt)
UA (1) UA116107C2 (pt)
WO (1) WO2014016433A1 (pt)
ZA (1) ZA201501209B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3372605B1 (en) 2008-10-22 2021-11-03 Array Biopharma, Inc. Substituted pyrazolo[1,5-a]pyrimidine compounds as trk kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
PL3205654T3 (pl) 2010-05-20 2019-08-30 Array Biopharma, Inc. Związki makrocykliczne jako inhibitory kinazy TRK
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2015143652A1 (en) * 2014-03-26 2015-10-01 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS,COMPOSITIONS AND METHODS THEREOF
BR112017007072A2 (pt) 2014-10-06 2018-01-30 Flatley Discovery Lab Llc compostos de triazolopiridina e métodos para o tratamento de fibrose cística
UA123044C2 (uk) 2014-11-16 2021-02-10 Ерей Біофарма Інк. КРИСТАЛІЧНА ФОРМА (S)-N-(5-((R)-2-(2,5-ДИФТОРФЕНІЛ)-ПІРОЛІДИН-1-ІЛ)-ПІРАЗОЛО[1,5-a]ПІРИМІДИН-3-ІЛ)-3-ГІДРОКСИПІРОЛІДИН-1-КАРБОКСАМІД ГІДРОСУЛЬФАТУ
EP3233840B1 (en) 2014-12-16 2018-11-21 Eudendron S.r.l. Heterocyclic derivatives modulating activity of certain protein kinases
EP3368039A1 (en) 2015-10-26 2018-09-05 The Regents of The University of Colorado, A Body Corporate Point mutations in trk inhibitor-resistant cancer and methods relating to the same
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
BR112018070304A2 (pt) 2016-04-04 2019-01-29 Loxo Oncology Inc formulações líquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida
BR112018073504A2 (pt) 2016-05-18 2019-03-26 Array Biopharma, Inc. processo para preparar (s)-n-(5-((r)-2-(2,5-difluorofenil)pirrolidin-1-il)-pirazol[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida e sais da mesma
US10246462B2 (en) 2016-09-09 2019-04-02 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
WO2018079759A1 (ja) * 2016-10-31 2018-05-03 塩野義製薬株式会社 ＴｒｋＡ阻害活性を有する縮合複素環および縮合炭素環誘導体
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
EP3822270A4 (en) * 2018-05-02 2022-03-02 JW Pharmaceutical Corporation NEW HETEROCYCLIC DERIVATIVE
KR102129114B1 (ko) * 2018-07-26 2020-07-02 주식회사 온코파마텍 TrkA 저해 활성을 갖는 화합물 및 이를 유효성분으로 함유하는 통증의 예방 또는 치료용 약학적 조성물
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
CN110105356B (zh) * 2019-05-31 2022-04-01 四川国康药业有限公司 一种氮杂吲哚类化合物及其制备方法和用途
CN110935250A (zh) 2019-12-10 2020-03-31 科沃斯机器人股份有限公司 空气净化设备

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199902301T2 (xx) 1997-03-19 1999-12-21 Basf Aktiengesellschaft Pirilo $2,3D]pirimidinler ve onlar�n kullan�m�.
EP1215208B1 (en) 1997-10-27 2006-07-12 Agouron Pharmaceuticals, Inc. 4-Aminothiazole derivatives, their preparation and their use as inhibitors of cyclin-dependent kinases
CN100338047C (zh) 2000-06-22 2007-09-19 辉瑞大药厂 吡唑并嘧啶酮类的制备方法
SE0301906D0 (sv) * 2003-06-26 2003-06-26 Astrazeneca Ab New compounds
DE102004061288A1 (de) 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
CA2620254A1 (en) * 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 map kinase inhibitors and methods for using the same
WO2008010964A1 (en) 2006-07-17 2008-01-24 Merck & Co., Inc. 1-hydroxy naphthyridine compounds as anti-hiv agents
PL2120932T3 (pl) * 2006-12-20 2015-02-27 Nerviano Medical Sciences Srl Indazolowe pochodne jako inhibitory kinazy do leczenia raka
WO2008089307A2 (en) * 2007-01-18 2008-07-24 Lexicon Pharmaceuticals, Inc. Delta 5 desaturase inhibitors for the treatment of pain, inflammation and cancer
WO2008112695A2 (en) * 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
NZ583450A (en) * 2007-07-20 2012-05-25 Nerviano Medical Sciences Srl Substituted indazole derivatives active as kinase inhibitors
ES2630026T3 (es) 2008-12-18 2017-08-17 Nerviano Medical Sciences S.R.L. Derivados indazólicos sustituidos activos como inhibidores de cinasa
FR2970967B1 (fr) * 2011-01-27 2013-02-15 Pf Medicament Derives de type azaindazole ou diazaindazole comme medicament
EP2689778A1 (en) * 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain

Also Published As

Publication number Publication date
AU2013294920A1 (en) 2015-03-12
CN104684554B (zh) 2017-05-10
PT2877177T (pt) 2017-02-06
JP2019031542A (ja) 2019-02-28
WO2014016433A1 (en) 2014-01-30
ES2612349T3 (es) 2017-05-16
CN104684554A (zh) 2015-06-03
MA37866B1 (fr) 2016-12-30
IL236917A (en) 2016-11-30
JP6456823B2 (ja) 2019-01-23
HRP20170104T1 (hr) 2017-03-24
NZ705253A (en) 2017-05-26
KR102120505B1 (ko) 2020-06-08
JP2015522650A (ja) 2015-08-06
MA37866A1 (fr) 2016-05-31
TN2015000034A1 (en) 2016-06-29
CA2879595A1 (en) 2014-01-30
DK2877177T3 (en) 2017-02-06
CA2879595C (en) 2020-07-28
CY1118478T1 (el) 2017-07-12
MY183398A (en) 2021-02-18
PL2877177T3 (pl) 2017-04-28
LT2877177T (lt) 2017-01-25
MX363605B (es) 2019-03-26
EP2689778A1 (en) 2014-01-29
MX2015001009A (es) 2015-06-04
US20150190394A1 (en) 2015-07-09
EP2877177B1 (en) 2016-10-26
JP6732855B2 (ja) 2020-07-29
UA116107C2 (uk) 2018-02-12
SI2877177T1 (sl) 2017-02-28
BR112015001502B1 (pt) 2023-03-07
AU2013294920B2 (en) 2017-08-24
US9381195B2 (en) 2016-07-05
RU2015106434A (ru) 2016-09-20
RU2640046C2 (ru) 2017-12-26
RS55646B1 (sr) 2017-06-30
EP2877177A1 (en) 2015-06-03
KR20150038295A (ko) 2015-04-08
ZA201501209B (en) 2016-03-30
HK1207302A1 (en) 2016-01-29
HUE032919T2 (hu) 2017-11-28

Similar Documents

Publication Publication Date Title
BR112015001502A2 (pt) derivados de tipo azaindazol ou diazaindazol para tratamento de dor
PH12019501321B1 (en) Use of pyrazolopyrimidine derivatives for the treatment of pi3k-delta related disorders
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
EA201590371A1 (ru) 1,4-дизамещенные аналоги пиридазина и способы лечения связанных с дефицитом smn состояний
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
NZ708593A (en) Novel pyrazole derivative
MX347988B (es) Inhibidores de fosfatidilinositol 3-cinasa.
EA201491672A1 (ru) Гетероциклильные соединения как ингибиторы mek
MX355267B (es) Análogos de carba-nucleósido 2´-sustituidos para tratamiento antivírico.
NZ739760A (en) Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
UA110943C2 (uk) N-ацилсульфонамідні промотори апоптозу
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
BR112015023761A2 (pt) moduladores de molécula pequena de pcsk9 e seus métodos e usos
MY167898A (en) Co-crystals and salts of ccr3-inhibitors
MX340574B (es) Imidazo pirazinas.
BR112015004523A2 (pt) compostos de tetraciclina
EA201590364A1 (ru) Применение орвепитанта, его солей и кристаллических форм и композиций, его содержащих, для лечения зуда
IN2015DN01329A (pt)
IN2014KN01113A (pt)
BR112012006070A2 (pt) composições e métodos para tratar distúrbios convulsivos.
BR112015006243A2 (pt) agentes antibacterianos de fenicol
EA201491878A8 (ru) Замещенные ксантиновые производные

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/07/2013, OBSERVADAS AS CONDICOES LEGAIS